Adult atopic dermatitis and the risk of type 2 diabetes - 19/04/17
Doi : 10.1016/j.jaci.2016.08.049
Yuki M.F. Andersen, MD a, b 
, Alexander Egeberg, MD, PhD a, b, Gunnar H. Gislason, MD, PhD b, c, d, Lone Skov, MD, PhD, DMSc a, Filip K. Knop, MD, PhD e, Jacob P. Thyssen, MD, PhD, DMSc a, f
, Alexander Egeberg, MD, PhD a, b, Gunnar H. Gislason, MD, PhD b, c, d, Lone Skov, MD, PhD, DMSc a, Filip K. Knop, MD, PhD e, Jacob P. Thyssen, MD, PhD, DMSc a, f a Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
b Department of Cardiology, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
c Danish Heart Foundation, Copenhagen, Denmark
d National Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark
e Center for Diabetes Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
f National Allergy Research Centre, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
| Y.M.F.A. and J.P.T. are supported by an unrestricted grant from the Lundbeck Foundation. J.P.T.'s spouse is currently employed at Novo Nordisk. A. E. has received research funding and/or consultancy and speaker honoraria from Pfizer and Eli Lilly. G.H.G. and F.K.K. are supported by unrestricted research grants from the Novo Nordisk Foundation. |
|
| Disclosure of potential conflict of interest: Y. M. F. Andersen and J. P. Thyssen receive grant support from Lundbeck Foundation. A. Egeberg serves as a consultant for Eli Lilly and Pfizer; is an employee of Pfizer; receives research support from Eli Lilly and Pfizer; and receives payments for lectures from Pfizer, Eli Lilly, Galderma, Novartis, and Janssen. G. H. Gislason receives grant support from Pfizer, Bayer, Bristol-Myers Squibb, AstraZeneca, and Boehringer Ingelheim and holds stock options with Novo Nordisk A/S, Lundbeck A/S, and Alk-Abello A/S. L. Skov serves as a consultant for Regeneron. F. K. Knop received payment for lectures from AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk, Sanofi-Aventis, and Zealand Pharma. |
© 2016
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 139 - N° 3
P. 1057-1059 - mars 2017 Retour au numéro
Article précédent
- Cardiac magnetic resonance imaging for the diagnosis and follow-up of Loeffler's endocarditis
- Grazia Casavecchia, Matteo Gravina, Michele Correale, Antonio Totaro, Luca Macarini, Matteo Di Biase, Natale Daniele Brunetti
- Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria
- Janine Gericke, Martin Metz, Tatevik Ohanyan, Karsten Weller, Sabine Altrichter, Per Stahl Skov, Sidsel Falkencrone, Janko Brand, Arno Kromminga, Tomasz Hawro, Martin K. Church, Marcus Maurer
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?